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ПРОГНОЗ ВЫЖИВАЕМОСТИ БОЛЬНЫХ ПНЕВМОНИЕЙ С НАРУШЕНИЯМИ ИММУНИТЕТА
НА ФОНЕ ОНКОГЕМАТОЛОГИЧЕСКОЙ ПАТОЛОГИИ
ГУ «Днепропетровская медицинская академия МЗ Украины», Днепр, Украина
Цель исследования — определение факторов, обусловливающих выживаемость больных
пневмонией на основе изучения комплекса клинико-лабораторных, анамнестических и им-
мунологических показателей больных пневмонией с нарушениями иммунитета на фоне онко-
гематологической патологии.
Независимыми предикторами, которые непосредственно влияли на выживаемость больных
пневмонией на фоне онкогематологической патологии, были: грамотрицательные возбудители,
количество эритроцитов и нейтрофилов, количество курсов химиотерапии и показатель иммуно-
регуляторного индекса. Коварианты благоприятного прогноза: количество курсов химиотерапии
меньше 8; показатель количества эритроцитов больше 2,0·1012/л; показатель иммунорегулятор-
ного индекса больше 1,09. Коварианты неблагоприятного прогноза событий: количество курсов
химиотерапии 8 и больше; наличие грамотрицательных возбудителей; показатель количества
эритроцитов меньше 2,0·1012/л; показатель иммунорегуляторного индекса меньше 1,09.
Анализ выживаемости больных пневмонией на фоне онкогематологической патологии с
учетом ковариантов неблагоприятного развития событий доказал, что этот показатель в течение
месяца будет составлять 30 %, при благоприятном прогнозе — 96 %.
Ключевые слова: пневмония, выживаемость, нарушение иммунитета, летальный исход.
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The aim of the study: to determine the factors that cause the survival of patients with pneumonia,
based on the study of complex, clinical and laboratory, anamnestic and immunological parameters of
patients with pneumonia with immune disorders on the background of oncohematological pathology.
Materials and methods. To solve the problem, a computer database of the results of the exami-
nation of 811 patients with lesions of the broncho-pulmonary system on the background of oncohe-
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Relationship of
Work with Scientific
Programs, Plans, Themes
This research work is a part
of the planned comprehensive
research work of the Department
of Internal Medicine № 1 of the
State Establishment “Dnipropet-
rovsk Medical Academy of Health
Ministry of Ukraine”“Studying the
features of bronchopulmonary
disease (chronic bronchitis, asth-
ma, pneumonia) in the age as-
pect and develop schemes
for integrated prevention and
treatment”, state registration
N 0199U002120.
Introduction
The survival of patients is the
most important integrated indica-
tor of quality and effectiveness of
medical care for the population.
Most publications devoted to the
survival of patients with oncohe-
matological pathology are stud-
ies in which carried out a com-
parative analysis of the effective-
ness of various medical diagnos-
tic technologies, chemotherapy
regimens (CTs) and their modi-
fications for this indicator at dif-
ferent stages of treatment [1; 2;
9; 14; 18] or depending on the
form of hemoblastosis [3]. Mo-
dern CT patterns, developed in
accordance with the peculiarities
of the pathogenesis of nosologi-
cal forms of oncohematological
pathology, to a large extent al-
low control of tumor progression
and are the causes of the elon-
gation of the life expectancy of
such patients. Moreover, a sig-
nificant threat to the lives of pa-
tients with hematological pathol-
ogy are infectious complications
(IC), including the leading role
pneumonia and sepsis [17]. In
studies devoted to the diagnosis
of pneumonia in patients with im-
mune disorders on the back-
ground of oncohematological
pathology study microbiological
features [16], peculiarities of the
course and clinical picture [8].
Consequently, today attention is
paid to the factors influencing
the course of the underlying dis-
ease. Scientific studies that have
examined the issue comprehen-
sively virtually absent. Thus, de-
spite the relevance of this prob-
lem in scientific publications, not
enough attention is paid to de-
termining the factors that deter-
mine the mortality and survival
rate of patients with pneumonia
matological pathology was created. The study was conducted in two stages in the haematological
center “Multifunctional Clinical Hospital № 4”, Dnipro, 2010–2016. The retrospective stage included
the analysis of archival data of 535 cases of hospitalizations of patients with oncohematological pa-
thology; prospective phase — a study of 276 cases of hospitalizations. Diagnosis of oncohematologi-
cal diseases was determined according to generally accepted clinical and morphological criteria. The
diagnosis of pneumonia was verified in accordance with the “Order of the Ministry of Health of Ukraine
No. 128, March 19, 2007”. We studied and analyzed the indices that characterizing the general condi-
tion of the patient; anamnestic information about the course of the main disease and peculiarities of
the course of the broncho-pulmonary system disease in the dynamics. Features of infectious defeat
of the bronchopulmonary system in the studied patients were studied regardless of the phase of the
course of the underlying disease. The statistical processing of the research results was carried out
using descriptive and analytical biostatistics methods implemented in software packages STATISTI-
CA 6.1 (StatSoftInc., Serial No. AGAR909E415822FA); Microsoft Excel (Office Home Business 2KB4Y-
6H9DB-BM47K-749PV-PG3KT). Median (Me) as a measure of the central tendency was used to describe
the quantitative characteristics; interquartile scale ((25%, 75%) — 25 and 75 percentiles respectively, Q1
and Q3 — first and third quartiles) to describe the variation of attributes. In the statistical analysis of the
results of the study, the non-parametric dispersion analysis of Kraskele-Wallis and the correlation analysis
with the calculation of the Spirman rank correlation coefficients (с) were performed. Multiple comparisons
were made with Bonferon and Holm. Methods for assessing survival of patients were used: analysis of
lifetime tables and evaluation of Kaplan-Mayer’s survival function with the construction of survival curves;
logistic rank test with Yates correction for continuity; Cox proportional risk regression models were used
too. Univariate and multiple analysis conducted; the ratio of risks was determined.
The results of the study showed that the survival rate of patients with pneumonia on the back-
ground of oncohematological pathology was determined by the factors that characterized the course
of pneumonia, the course of oncological blood disease, indicators of immune reactivity.
Independent predictors influencing the survival of patients with pneumonia on the background of
oncohematological pathology determined the indicators: gram-negative pathogens, the number of eryth-
rocytes and neutrophils, the number of courses of HT and the immunoregulatory index. The covari-
ates of the favorable forecast of events are defined: the number of HT courses is less than 8; not
determined in the patient gram-negative pathogens; the number of erythrocytes more than 2.0·1012/l;
the immunoregulatory index is more than 1.09. Covariant of unfavorable forecast of events determined:
number of chemotherapy courses 8 and more; the presence of gram-negative pathogens; the number
of erythrocytes is less than 2.0·1012/l; the immunoregulatory index is less than 1.09. Analysis of sur-
vival of patients with pneumonia with immunity disorders on the background of oncohematological
pathology with covariates of unfavorable development of events, proved that the survival rate during
the month will be 30%, with a favorable prediction of the development of events — 96%.
Prospects for further research. A promising further study of factors that affect lethality and cause
survival of patients with pneumonia on the background of oncohematological pathology.
Key words: pneumonia, survival of patients, immunity disorders, lethal outcome, factors of poor
prognosis.
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in patients with immune disor-
ders on the background of onco-
hematological pathology.
The aim of the study: to de-
termine the factors that cause
the survival of patients with
pneumonia, based on the study
of complex, clinical and labo-
ratory, anamnestic and immuno-
logical parameters of patients
with pneumonia with immune
disorders on the background of
oncohematological pathology.
Materials and Methods
To solve the problem, a com-
puter database of the results of
the examination of 811 patients
with lesions of the broncho-pul-
monary system on the back-
ground of oncohematological pa-
thology was created. The study
was conducted in two stages in
the haematological center “KZ
multifunctional clinical hospital
No. 4”, Dnipro, 2010–2016. The
retrospective stage included the
analysis of archival data of 535
cases of hospitalizations of pa-
tients with oncohematological
pathology; prospective phase —
a study of 276 cases of hospita-
lizations. Diagnosis of oncohe-
matological diseases was deter-
mined according to generally
accepted clinical and morpholog-
ical criteria [10]. The diagnosis of
pneumonia was verified in ac-
cordance with the “Order of the
Ministry of Health of Ukraine
No. 128, March 19, 2007” [5]. We
studied and analyzed the indices
that characterizing the general
condition of the patient; anamnes-
tic information about the course of
the main disease and peculiari-
ties of the course of the broncho-
pulmonary system disease in the
dynamics. Features of infectious
defeat of the bronchopulmonary
system in the studied patients
were studied regardless of the
phase of the course of the un-
derlying disease. The statistical
processing of the research re-
sults was carried out using de-
scriptive and analytical biosta-
tistics methods implemented
in software packages STATISTI-
CA 6.1 (StatSoftInc., Serial
No. AGAR909E415822FA); Mic-
rosoft Excel (Office Home Busi-
ness 2KB4Y-6H9DB-BM47K-
749PV-PG3KT). Median (Me) as
a measure of the central ten-
dency was used to describe the
quantitative characteristics; in-
terquartile scale ((25%, 75%) —
25 and 75 percentiles respec-
tively, Q1 and Q3 — first and
third quartiles) to describe the
variation of attributes. In the sta-
tistical analysis of the results of
the study, the non-parametric
dispersion analysis of Kraskele–
Wallis and the correlation ana-
lysis with the calculation of the
Spirman rank correlation coeffi-
cients (ρ) were performed. Mul-
tiple comparisons were made
with Bonferon and Holm. Statis-
tically significant was the value
of the significance level p<0.05
(5%) [4]. An analysis of survival
was conducted — an assess-
ment of the likelihood that the
patient will remain alive before a
particular point after the start of
treatment (in our case, until the
end of inpatient treatment).
As the observation time for
each patient using the time inter-
val between the date of hospital-
ization for blood cancer against
which there was pneumonia and
the date of death or discharge
from the hospital. Methods for
assessing the survival rate of
patients were: analysis of mor-
tality table tables and Kaplan–
Meier method survival estimation
with the construction of survival
curves that characterize the pro-
bability of surviving a certain mo-
ment of time after the onset of
an initial event. The last method
allows us to take into account
the specificity of the time of life
data, which is connected, first of
all, with their incompleteness
(censored data): patients during
the observation may appear for
one reason or another, that is,
the real lifetime of such people
is greater than the duration of
their observation. The peculiari-
ty of the data obtained in the
study is the deviation of the dis-
tribution of life time from the nor-
mal law. In this regard, nonpara-
metric criteria are used when
comparing survival curves: for
the characterization of the aver-
age life expectancy, the median
survival rate was used with
a 95% confidence interval (CI),
which characterized the time
point to which half (50%) of the
population under study survives.
To evaluate the probability of the
difference in survival rates be-
tween the groups, a log-rank test
with Yates correction for continu-
ity was used [4]. Cox proportion-
al-hazards regression models
were used to analyze the influ-
ence of the investigated factors
on survival, to evaluate the rela-
tionships between multidimen-
sional continuous and binary va-
riables with survival time values.
An analysis of the impact of each
individual indicator on the time
from the beginning of the obser-
vation to the occurrence of the
event (univariate analysis) and
subsequent multiple analysis,
which included all the indicators
that, according to the previous
analysis, influenced the occur-
rence of the event (p<0.05). The
relation of risks (HR, HR risk atio)
was defined, which is interpreted
as the ratio of intensities in the
Poisson regression. In such cas-
es, the values above the unit in-
dicate an increased risk, values
below unit 1 are reduced risk, and
unit levels indicate that there is no
increased or reduced risk of
reaching the endpoint [7].
Results and Discussion
Of the 881 patients who had
been diagnosed with IU in the
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background of program treat-
ment: 270 (33.29%) patients
had bronchitis (1 group); in 162
(19.98%) patients (group 2) —
pneumonia without severe pul-
monary complications and with a
positive conclusion of pneumo-
nia; in 112 (13.81%) — severe
pneumonia with complications
(bilateral lung disease, pleurisy,
hemoptysis, respiratory failure)
with positive completion of
pneumonia (group 3); in 267
(32.92%) — pneumonia with a
lethal consequence (group 4).
Of the total number of hospi-
talizations: 258 patients were the
main primary illness, which was
31.81%; hospitalized because of
pneumonia — 98 patients, which
was 12.08%; Hospitalized pa-
tients due to the need to conduct
HT in accordance with the stage
and form of oncological disease
of the blood — 455 patients,
which was 56.10%.
Characteristics of patients in
the study group on oncohema-
tological diseases was as follows:
patients with chronic lymphocytic
leukemia — 152 (18.74%), chro-
nic myeloid leukemia — 80
(9.86%); myeloma (MH) — 116
(14.3%), acute leukemia (AL) —
184 (22.69%) (of which acute
lymphocytic leukemia is 92
(11.34%), acute myeloid leuke-
mia — 80 (9.86%), subleukemic
myelosis — 10 (1.23%), acute
monoblast leukemia — 2 (0.25%));
aplastic anemia (AA) — 83
(10.23%), Valdenstrem disease
(VD) — 47 (5.8%), lymphoma —
46 (5.67%), myelodysplastic
syndrome — 33 (4.07%), eryth-
remia — 31 (3.82%), skin’s
melanoma — 7 (0.86%), idio-
pathic thrombocytopenic purpu-
ra — 24 (2.96%), lymphoprolif-
erative diseases — 4 (0.49%),
and others — 8 (0.98%) (throm-
bosis, hemorrhagic vasculitis,
lymphosarcoma, extracellular
plasmacytoma). The ratio of wo-
men to men is 2 : 3.
An estimate of the theoretical
distribution of the survival func-
tion is presented in Fig. 1
The evaluation of the theoret-
ical distribution of the survival
function has shown that the most
suitable family of distributions for
the data obtained by the study
groups is the distribution of the
Gompertz: in this distribution
there is no significant difference
from the observed values in the
evaluation of parameters, fitting
in the third way (corresponding
to weight 3) shows satisfactory
agreement with the data (by cri-
terion χ2 — p=0,079). Thus, by
statistical methods, we have de-
termined that the distribution of
Gompertz fully describes the
survival function of patients in
study groups.
The curve of overall survival
of patients with pneumonia on
the background of oncohemato-
logical pathology, which is based
on the Kaplan–Meier method is
presented in Fig. 2.
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Fig. 1. Estimates of the theoretical distribution of the survival function
(according to the criterion χ2 for the model 1 — p=0.001; 2 — p=0.029;
3 — p=0.079); 1′ — observed; 2′ — Weight 1; 3′ — Weight 2; 4′ — Weight 3
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Fig. 2. Total cumulative survival for patients with pneumonia on the back-
ground of oncohematological pathology
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The median survival rate for
the examined patients was 36.0
(CI 34.0–39.0) days in total;
the 25th percent survival rate
was 19.0 days; the 75th percent
survival rate was 51.0 days. At
the time of the analysis, the cu-
mulative survival rates for the
examined patients in general for
the analyzed period were: the
probability of living ≥1 month
was 61.32% (95% CI 56.73–
65.91); ≥ 2 months — 17.38%
(95% CI 9.88–24.88); ≥ 4 months
— 2.21% (95% CI 0–6.32).
Cumulative survival of pa-
tients 1, 2, 3 and 4 groups with
pathology of the broncho-pulmo-
nary system on the background
of oncohematological pathology
is presented in Fig. 3.
The conducted analysis of
survival of patients with pneumo-
nia on the background of onco-
hematological pathology gene-
rally concerned mainly patients
3rd and 4th group, as for pa-
tients in the 1st and 2nd groups
of the study during the observa-
tion, survival was almost 100%:
in 1 group of patients — 98.89%,
in the 2nd — 99.38%. This fact
allows us to conclude that the
overall cumulative survival for
patients in general characteriz-
es, basically, the survival of pa-
tients with severe pneumonia,
including pneumonia with severe
complications.
The overall survival of pa-
tients with pneumonia on the
background of oncohematologi-
cal pathology, depending on the
stage of the underlying disease
according to the Ann-Arbor clas-
sification is presented in Fig. 4
In the analysis of cumulative
survival for the Ann-Arbor clas-
sification, significant differences
between the groups were deter-
mined (log-rank test, p<0.001).
For patients with stage I of on-
cohematological disease, ac-
cording to the Ann-Arbor classi-
fication, the total cumulative sur-
vival for 1 month was 66.1%
(95% CI 55.95–76.25); for pa-
tients with stage II — 61.9 (95%
CI 54.63–69.17); for patients
with the III stage — 57.4 (95%
CI 48.91–65.89); for patients
with the IV stage — 18.1 (95%
CI 2.2–34.0). Consequently, the
higher stage of the Ann-Arbor
classification was, the overall
cumulative survival rate of the
patients was less.
Cumulative survival of pa-
tients with pneumonia on the
background of oncohematologi-
cal pathology, depending on the
degree of neutropenia present-
ed in Fig. 5 and in Table 1.
Analysis of the survival rate of
patients with pneumonia in the
background of oncohematologi-
cal pathology, depending on the
degree of neutropenia showed
that the probability of the onset
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Fig. 3. Total cumulative survival for patients with pneumonia on the back-
ground of oncohematological pathology: 1 — group 1; 2 — group 2; 3 —
group 3; 4 — group 4
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of the lethal consequence of
pneumonia within one month is
highest in patients with neutro-
penia of grade 3: the median
surviving bridge was 19.0 days
(95% CI 14.0–28.0)) and signifi-
cantly differed from the indicator
of other groups (log-rank test,
p<0.001). The survival rate of
patients with neutropenia of
grade 2 was 36.0 days (95% CI
30.0–46.0)); the survival rate of
patients with neutropenia of
grade 1 was 46.0 days (95% CI
36.0–76.0)). Consequently, with
an increase in the degree of neu-
tropenia, the possibility of surviv-
al in the patient was less.
It should be noted that the
group of patients without neu-
tropenia for survival did not dif-
fer from the group of patients
with neutropenia of 1 degree
(p=0.326).
Factors influencing survival of
patients were determined by an-
alyzing Cox proportional risks
with the definition of BP as
coarse (uncorrected) based on
the analysis of the individual
effects of each factor (univari-
ate analysis) and corrected BP
by means of multiple analysis.
The results of the analysis (ad-
justed and coarse Risk Ratio
Indicators) in determining the
factors influencing the surviv-
al of patients with pneumonia
in the background of oncolog-
ical pathology (survival predic-
tors) by the proportional Cox
risk model are presented in
Table. 2.
All the analyzed parameters
(see Table 2) were associated
with an increased risk of a lethal
outcome of pneumonia in a uni-
variate analysis (p<0.001). Ac-
cording to the results of the mul-
tiple analysis of proportional Cox
intensities, the independent
predictors of the lethal out-
come of pneumonia were deter-
mined: the number of HT cours-
es, gram-negative pathogens,
glycemia, wet wheezing, pulse
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Fig. 5. Cumulative survival of patients with pneumonia in the background
of oncohematological pathology, depending on the degree of neutropenia:
1 — 1 stage; 2 — 2 stage; 3 — 3 stage; 4 — 4 stage
Log-rank test; p<0.001
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Table 1
Cumulative survival of patients with pneumonia
in the background of oncohematological pathology,
depending on the degree of neutropenia
        
Survival by
             Total cumulative survival       
Median survival
    
individual groups
                during 1 month
% 95% CІ days 95% CІ
Without neutropenia 68.5 59.74–77.26 40.0 36.0–56.0
Neutropenia 1 st. 75.5 67.58–83.42 46.0 36.0–76.0
Neutropenia 2 st. 59.8 49.2–70.4 36.0 30.0–46.0
Neutropenia 3 st. 35.6 27.54–43.66 19.0 14.0–28.0
log-rank test, р<0.001
Table 2
Factors for predicting the survival of patients with pneumonia in the background of
oncohematological pathology according to the proportional Cox risk model
          Kind of analysis of proportional intensity of Cox
             Predictors of survival univariant                               multiple
RR rude 95% CІ р RR adjusted 95% CІ р
Gram-negative pathogens (presence) 4.32 3.17–5.90 < 0.001 2.12 1.49–3.01 < 0.001
Courses HТ “8 and more” 2.46 1.95–3.1 < 0.001 1.50 1.16–1.95 0.002
Hemoptysis (presence) 2.29 1.7–3.07 < 0.001 1.27 0.89–1.81 0.183
Glycemia 2.75 2.13–3.54 < 0.001 1.34 1.0–1.77 0.047
Neutropenia 3 st. 2.77 2.19–3.52 < 0.001 1.35 0.86–2.09 0.189
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Table 3
Indicators of survival of patients with pneumonia
in the background of oncohematological pathology,
depending on certain predictors of
the lethal outcome of pneumonia
       
Survival by
            Total cumulative survival      
Median of survival
   
individual groups
            during 1 month, %
% 95% CI days 95% CI
CHT more than 8 courses (log-rank test, р<0.001)
No 72 66.79–77.21 45.0 37.0–52.0
Yes 42.1 34.57–49.63 28.0 28.0–30.0
Gram-negative pathogens (log-rank test, р<0.001)
No 83.6 77.43–89.77 67.0 45.0–67.0
Yes 43.6 37.76–49.44 28.0 27.0–31.0
Glycemia (log-rank test, р<0.001)
No 75.7 69.66–81.74 52.0 40.0–76.0
Yes 44.7 38.37–51.03 29.0 28.0–33.0
Wet wheezing (log-rank test, р<0.001)
No 66.6 61.33–71.87 40.0 38.0–48.0
Yes 28.9 20.26–37.54 16.0 13.0–23.0
Pulse rate > 92 (log-rank test, р<0.001)
No 74.6 68.99–80.21 46.0 40.0–56.0
Yes 31.8 25.04–38.56 19.0 14.0–24.0
Erythrocytes = 2 (log-rank test, р<0.001)
No 77.4 71.52–83.28 52.0 38.0–76.0
Yes 32.1 25.81–38.39 19.0 15.0–24.0
СD4/СD8 ≤ 1,09 (log-rank test, р<0.001)
No — — — —
Yes 39.1 25.03–53.17 28.0 16.0–33.0
End of Table 2
Wet wheezing (presence) 2.97 2.32–3.8 < 0.001 1.44 1.1–1.88 0.008
Pulse rate, in min. 1.04 1.04–1.05 < 0.001 1.02 1.01–1.03 < 0.001
Leukocytes,  ⋅109/l 0.74 0.67–0.81 < 0.001 0.93 0.79–1.08 0.325
Hemoglobin, g/l 0.98 0.98–0.98 < 0.001 1.0 0.99–1 0.008
Erythrocytes, ⋅1012/l 0.48 0.42–0.55 < 0.001 0.69 0.58–0.81 < 0.001
Thrombocytes, ⋅109/l 1.0 1.0–1.0 < 0.001 1.0 1.0–1.0 0.461
Lymphocytes, % 0.94 0.92–0.95 < 0.001 0.98 0.96–1.01 0.144
B CD19, % 0.89 0.85–0.94 < 0.001 0.99 0.91–1.09 0.981
T CD19, % 1.04 1.02–1.05 < 0.001 1.0 0.98–1.02 0.955
СD4, % 0.94 0.92–0.95 < 0.001 0.96 0.92–1.01 0.085
СD4/СD8=1,09 0.19 0.12–0.3 < 0.001 2.90 1.09–9.23 0.050
CD56, % 0.79 0.75–0.83 < 0.001 1.0 0.9–1.13 0.881
IgG, g/l 0.8 0.72–0.89 < 0.001 0.93 0.81–1.05 0.246
NST-stimulated test, unit. 0.94 0.92–0.96 < 0.001 0.98 0.95–1.0 0.067
Number of neutrophils, ⋅109/l 0.53 0.44–0.64 < 0.001 0.98 0.95–1.0 0.131
          Kind of analysis of proportional intensity of Cox
             Predictors of survival univariant multiple
RR rude 95% CІ р RR adjusted 95% CІ р
rate, hemoptysis, the number of
red blood cells, hemoglobin, the
number of lymphocytes, plate-
lets, neutrophils, cellular immu-
nity indexes absolute values, in-
dicators of humoral immunity,
immunoregulatory index (see
Table 2).
Independent predictors of the
lethal outcome of pneumonia are
given in Table 3.
A meaningful (p<0.001) pro-
portional Cox survival model
was constructed, based on the
obtained data on independent
factors in the prognosis of sur-
vival of patients with pneumonia
on the background of oncohe-
matological pathology. This
model included the following
predictors (significance level
p<0.01): HT courses “8 and more”
presence of gram-negative pa-
thogens, erythrocyte count, im-
munoregulatory index (CD4/
CD8) (Table 4). Other inde-
pendent predictors were not in-
cluded in the model because of
insignificant influence on Wald’s
statistics.
The probability of the end-
point (the patient’s death) ac-
cording to the Cox regression
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model of proportional risk is
modeled as follows:
H (t) = H0 (t) · exp (β1·x1 +
+ β2·x2 + β3·x3 +β4·x4),
where β1–β4 — regression
coefficients; x1–x4 — predictive
variables presented in the
Table 4; H0 (t) is the basic dan-
ger at time t representing the risk
of death for a patient with a va-
lue of 0 for all predictive va-
riables.
Based on this, the ratio of
risks is calculated by the for-
mula:
Ln (H (t) / H0 (t)) =
= β1·x1 + β2·x2 +
+ β3·x3 + β4·x4.
Risk Ratio (RR) is the degree
of risk associated with each va-
riable (an independent predictor)
when fixing all other variables.
For a dichotomous variable (1 is
an existing risk factor, 0 is ab-
sent), the risk ratio 1 means that
the patient’s risk of death is the
same regardless of whether he
has the relevant characteristic or
not.
RR for more than 1 indicates
an increased risk for patients with
this characteristic; less than 1 —
at reduced risk. If the factor is
continuous, then the value of BP
is the instantaneous relative risk
of an event at any time for a per-
son with an increase of 1 in the
predictor’s value compared to
another person, since the two
values are the same for all oth-
er covariates. In general, RR is
the final value of the increased
risk for each unit or the level of
growth of the predictor variable
[4]. Regression coefficients (beta-
weights) are the weights for each
variable in the equation. Positive
coefficients of regression with
predictive variables indicate an
increase in risk and deterioration
of the forecast when they are
present. Negative regression
factors mean a more favorable
prognosis for patients with high-
er variables. In our study, it was
determined that predictors of “8
courses of HT and more” and
gram-negative pathogens are
positive regression coefficients.
Their presence in patients de-
termines the increase in the risk
of death and, thus, the deterio-
ration of the prediction of surviv-
al. Negative coefficients of re-
gression in our study were de-
termined: the number of red
blood cells and the immunoreg-
ulatory index. This means that
with an increase in these indi-
cators for patients, a more fa-
vorable prognosis is deter-
mined.
Thus, based on the received
regression model of Cox propor-
tional risks with the determined
independent predictors, the pro-
bability of dying during the first
month after hospitalization for a
patient with pneumonia in the
background of oncohematolo-
gical pathology is greater by
1.71 times with the number of
courses HT “more than 8”; in the
presence of a patient with gram-
negative pathogens of pneumo-
nia — greater 2.92 times. Con-
versely, the survival rate of pa-
tients with pneumonia in the
background of oncohematologi-
cal pathology is statistically sig-
nificantly increased with an in-
crease in the number of erythro-
cytes and immunoregulatory in-
dex. Adjusted RR for erythro-
cytes is 0.64 (95% CI 0.55–
0.74), for the immunoregulatory
index (CD4/CD8) — 0.48 (95%
CI 0.30–0.79).
The basic integral death risk
function can be used to calculate
the probability of survival S (t) for
any case at time t:
        S(t) = exp(-Н0(t) · PI), (3)
where PI — prognostic index
PI = x1·β1 + x2·β2 +
+ x3·β3 + x4·β4.
Survival curve of patients with
pneumonia background of onco-
hematological pathology for co-
variate adverse events: number
of courses HТ 8 and more; the
presence of gram-negative path-
ogens; the number of erythro-
cytes — 2.0·1012/l; the index of
immunoregulatory index (СD4/
СD8) — 1.09, is shown in
Fig. 6.
When constructing the surviv-
al curve of patients with pneumo-
nia with immunity disorders on
the background of oncohemato-
logical pathology for covariate
adverse events: with the number
of courses HT of 8 and more; the
(1)
(2)
(4)
Table 4
The regression model of Cox proportional risks of the influence of independent factors of
the prognosis of the risk of a lethal outcome of patients with oncohematological diseases on
the background of which there was a pneumonia
                            
Factors
Regression Standard Wald’s p-value χ2
RR 95% CІ
coefficient β error β χ2 Wald's
HT courses “8 and more” (х1) 0.535 0.123 18.98 0.001 1.71 1.34–2.17
presence of gram-negative pathogens (х2) 1.071 0.163 43.14 <0.001 2.92 2.11–4.02
Erythrocyte (х3) -0.521 0.071 53.99 <0.001 0.59 0.52–0.68
СD4/СD8 (х4) -0.725 0.247 8.64 0.003 0.48 0.30–0.79
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presence of gram-negative pa-
thogens; an indicator of the num-
ber of erythrocytes less than
2.0·1012/l; the value of the index
of immunoregulatory index is
less than 1.09, it is determined
that survival of patients with
pneumonia with immunity disor-
ders on the background of onco-
hematological pathology during
the month will be 30%.
The curve of cumulative sur-
vival of patients with pneumonia
with immunity disorders on the
background of oncohematologi-
cal pathology with the number of
courses of HT less than 8; not
defined in the patient gram-nega-
tive pathogens; the number of
erythrocytes more than 2.0·1012/l;
the immunoregulatory index
more than 1.09, is presented in
Fig. 7.
When constructing the surviv-
al curve of patients with pneumo-
nia with immunity disorders on
the background of oncohemato-
logical pathology with a favor-
able prognosis of the develop-
ment of events (with the number
of courses of HT less than 8; not
determining the patient gram-
negative pathogens, the number
of erythrocytes = 2.0·1012/l, the
values of the immunoregulatory
index (CD4/CD8)=1.09), the sur-
vival rate of patients with pneu-
monia for the month will be 96%.
In the study among the inde-
pendent predictors of survival of
patients with pneumonia are the
number of red blood cells and
hemoglobin levels. Some schol-
ars also testify that there is a
probable relationship between
the clinical manifestations of
anemic syndrome and survival
rates in patients with chronic
lymphocytic leukemia. A de-
crease in hemoglobin to less
than 100 g/l is associated with a
decrease in the median of over-
all survival to 93 days versus
160 days in patients with hemo-
globin levels greater than 100 g/l
[6]. In a recent study, regarding
survival rates of patients de-
pending on nosological forms of
oncohematological pathology, it
was determined that survival of
patients with chronic forms is
higher compared to acute leuke-
mias [3]. In the same study, the
age of patients is also consid-
ered as a factor affecting the
mortality rate. Patients with on-
cohematologic pathology have
immunity disorders, which deep-
en the inflammatory reaction in
pneumonia. Thus, the state of
the immune response can affect
the course of the disease and
determine the prognosis. In the
study, the following data were
obtained: the parameters of cel-
lular and humoral immunity are
independent predictors of surviv-
al of patients with pneumonia on
the background of oncohemato-
logical diseases. Since the de-
velopment of IC and pneumonia
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Fig. 6. Cumulative survival of patients with pneumonia with immunity
disorders on the background of oncohematological pathology at: number
of HT courses 8 and more; the presence of gram-negative pathogens; the
number of erythrocytes ≥ 2.0·1012/l; values of СD4/СD8 ≤ 1.09
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Fig. 7. Cumulative survival of patients with pneumonia with immunity
disorders on the background of oncohematological pathology with the
number of courses HT less than 8; not defined in the patient gram-nega-
tive pathogens; the number of erythrocytes ≥ 2.0·1012/l; values of СD4/
СD8 ≥ 1.09
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in patients with background of
oncohematological disease is
often associated with neutrope-
nia, it was logical to include this
indicator for the analysis of rela-
tionships with fatalities. The re-
sults of the study prove the con-
nection between the number of
neutrophils and the survival rate
of patients with pneumonia. The
obtained data coincide with the
data of other authors [13]. Au-
thors studying the course of
pneumonia in patients on the
background of oncohematologi-
cal pathology emphasize that it
has certain features depending
on the main oncological blood
disease [11] and the etiological
factor [12]. In the study on a suf-
ficient amount of material, it has
been determined that the num-
ber of HT courses preceding the
onset of pneumonia and gram-
negative pathogens of pneumo-
nia has been identified as inde-
pendent survivors.
Conclusions
1. The results of the study
showed that the survival rate of
patients with pneumonia on the
background of oncohematologi-
cal pathology was determined by
the factors that characterized the
course of pneumonia (the pres-
ence of gram-negative patho-
gens, hemoptysis), the course of
oncological blood disease (the
number of courses of HT pre-
ceding pneumonia, anemia, gly-
cemia, leukopenia, neutropenia,
thrombocytopenia), as well as
indicators of immune reactivity
(lymphocytopenia, indicators of
cellular and humoral immunity in
absolute numbers, immunoreg-
ulatory index).
2. Independent predictors in-
fluencing the survival of patients
with pneumonia on the back-
ground of oncohematological pa-
thology determined the indica-
tors: gram-negative pathogens,
the number of erythrocytes and
neutrophils, the number of cour-
ses of HT and the immunoregu-
latory index. The covariates of
the favorable forecast of events
are defined: the number of HT
courses is less than 8; not de-
termined in the patient gram-
negative pathogens; the number
of erythrocytes more than 2.0 ×
× 1012/l; the immunoregulatory
index is more than 1.09. Covari-
ant of unfavorable forecast of
events determined: number of
chemotherapy courses 8 and
more; the presence of gram-
negative pathogens; the number
of erythrocytes is less than 2.0 ×
× 1012/l; the immunoregulatory
index is less than 1.09.
3. Analysis of survival of pa-
tients with pneumonia with im-
munity disorders on the back-
ground of oncohematological
pathology with covariates of un-
favorable development of events,
proved that the survival rate dur-
ing the month will be 30%, with
a favorable prediction of the de-
velopment of events — 96%.
Prospects for further re-
search. A promising further
study of factors that affect lethali-
ty and cause survival of patients
with pneumonia on the back-
ground of oncohematological
pathology.
Ключові слова: пневмонія,
виживаність, порушення імуні-
тету, летальний кінець.
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